Plant Name: Uncaria macrophylla
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| GPBAR1; ADRA2C; ADRA2A; | |
| TSHR; OPRD1; NMUR2; | |
| PTPN1; PTPN2; ACP1; PTPRF; | |
| CTDSP1; RECQL; ALPL; TDP1; HSD11B1; HSD17B1; AKR1B1; HSD17B10; AKR1B10; ALOX15; NOX4; ALDH1A1; HSD17B2; APEX1; POLB; | |
| GAA; BCHE; ACHE; | |
| DAPK1; MAPK1; FLT3; | |
| CA2; CA1; CA12; CA9; CA5A; CA5B; CA3; CA14; CA7; CA4; CA6; | |
| AR; | |
| RORC; | |
| NR1H4; | |
| ESRRA; | |
| ALOX5; TYR; XDH; | |
| MMP1; MMP2; MMP9; | |
| AHR; HIF1A; TP53; NFKB1; | |
| ABCG2; ABCC1; | |
| LMNA; | |
| SMN1;SMN2; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| ATP-binding cassette | ABCG2 | ATP-binding cassette sub-family G member 2 | Q9UNQ0 | CHEMBL5393 |
| ATP-binding cassette | ABCC1 | Multidrug resistance-associated protein 1 | P33527 | CHEMBL3004 |
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
| Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
| Cytochrome P450 family 2 | CYP2C19 | Cytochrome P450 2C19 | P33261 | CHEMBL3622 |
| Cytochrome P450 family 2 | CYP2C9 | Cytochrome P450 2C9 | P11712 | CHEMBL3397 |
| Cytochrome P450 family 2 | CYP2A6 | Cytochrome P450 2A6 | P11509 | CHEMBL5282 |
| Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
| Enzyme_unclassified | HSD11B1 | 11-beta-hydroxysteroid dehydrogenase 1 | P28845 | CHEMBL4235 |
| Enzyme_unclassified | HSD17B1 | Estradiol 17-beta-dehydrogenase 1 | P14061 | CHEMBL3181 |
| Enzyme_unclassified | AKR1B1 | Aldose reductase | P15121 | CHEMBL1900 |
| Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
| Enzyme_unclassified | AKR1B10 | Aldo-keto reductase family 1 member B10 | O60218 | CHEMBL5983 |
| Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
| Enzyme_unclassified | NOX4 | NADPH oxidase 4 | Q9NPH5 | CHEMBL1250375 |
| Enzyme_unclassified | ALDH1A1 | Aldehyde dehydrogenase 1A1 | P00352 | CHEMBL3577 |
| Enzyme_unclassified | HSD17B2 | Estradiol 17-beta-dehydrogenase 2 | P37059 | CHEMBL2789 |
| Enzyme_unclassified | APEX1 | DNA-(apurinic or apyrimidinic site) lyase | P27695 | CHEMBL5619 |
| Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
| Enzyme_unclassified | CTDSP1 | Carboxy-terminal domain RNA polymerase II polypeptide A small phosphatase 1 | Q9GZU7 | CHEMBL1795098 |
| Enzyme_unclassified | RECQL | ATP-dependent DNA helicase Q1 | P46063 | CHEMBL1293236 |
| Enzyme_unclassified | ALPL | Alkaline phosphatase, tissue-nonspecific isozyme | P05186 | CHEMBL5979 |
| Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
| Hydrolase | GAA | Lysosomal alpha-glucosidase | P10253 | CHEMBL2608 |
| Hydrolase | BCHE | Butyrylcholinesterase | P06276 | CHEMBL1914 |
| Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
| Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
| Lyase | CA1 | Carbonic anhydrase I | P00915 | CHEMBL261 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
| Lyase | CA5A | Carbonic anhydrase VA | P35218 | CHEMBL4789 |
| Lyase | CA5B | Carbonic anhydrase VB | Q9Y2D0 | CHEMBL3969 |
| Lyase | CA3 | Carbonic anhydrase III | P07451 | CHEMBL2885 |
| Lyase | CA14 | Carbonic anhydrase XIV | Q9ULX7 | CHEMBL3510 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
| Lyase | CA6 | Carbonic anhydrase VI | P23280 | CHEMBL3025 |
| Metallo protease | MMP1 | Matrix metalloproteinase-1 | P03956 | CHEMBL332 |
| Metallo protease | MMP2 | Matrix metalloproteinase-2 | P08253 | CHEMBL333 |
| Metallo protease | MMP9 | Matrix metalloproteinase 9 | P14780 | CHEMBL321 |
| Methyl-lysine/arginine binding protein | SMN1;SMN2 | Survival motor neuron protein | Q16637 | CHEMBL1293232 |
| Nuclear hormone receptor subfamily 1 group F | RORC | Nuclear receptor ROR-gamma | P51449 | CHEMBL1741186 |
| Nuclear hormone receptor subfamily 1 group H | NR1H4 | Bile acid receptor FXR | Q96RI1 | CHEMBL2047 |
| Nuclear hormone receptor subfamily 3 group B | ESRRA | Estrogen-related receptor alpha | P11474 | CHEMBL3429 |
| Nuclear hormone receptor subfamily 3 group C | AR | Androgen Receptor | P10275 | CHEMBL1871 |
| Oxidoreductase | XDH | Xanthine dehydrogenase | P47989 | CHEMBL1929 |
| Oxidoreductase | ALOX5 | Arachidonate 5-lipoxygenase | P09917 | CHEMBL215 |
| Oxidoreductase | TYR | Tyrosinase | P14679 | CHEMBL1973 |
| Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
| Peptide receptor (family A GPCR) | OPRD1 | Delta opioid receptor | P41143 | CHEMBL236 |
| Peptide receptor (family A GPCR) | NMUR2 | Neuromedin-U receptor 2 | Q9GZQ4 | CHEMBL1075144 |
| Protein Kinase | DAPK1 | Death-associated protein kinase 1 | P53355 | CHEMBL2558 |
| Protein Kinase | MAPK1 | MAP kinase ERK2 | P28482 | CHEMBL4040 |
| Protein Kinase | FLT3 | Tyrosine-protein kinase receptor FLT3 | P36888 | CHEMBL1974 |
| Protein Phosphatase | PTPN1 | Protein-tyrosine phosphatase 1B | P18031 | CHEMBL335 |
| Protein Phosphatase | PTPN2 | T-cell protein-tyrosine phosphatase | P17706 | CHEMBL3807 |
| Protein Phosphatase | ACP1 | Low molecular weight phosphotyrosine protein phosphatase | P24666 | CHEMBL4903 |
| Protein Phosphatase | PTPRF | Receptor-type tyrosine-protein phosphatase F (LAR) | P10586 | CHEMBL3521 |
| Small molecule receptor (family A GPCR) | GPBAR1 | G-protein coupled bile acid receptor 1 | Q8TDU6 | CHEMBL5409 |
| Small molecule receptor (family A GPCR) | ADRA2C | Alpha-2c adrenergic receptor | P18825 | CHEMBL1916 |
| Small molecule receptor (family A GPCR) | ADRA2A | Alpha-2a adrenergic receptor | P08913 | CHEMBL1867 |
| Transcription Factor | AHR | Aryl hydrocarbon receptor | P35869 | CHEMBL3201 |
| Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
| Transcription Factor | TP53 | Cellular tumor antigen p53 | P04637 | CHEMBL4096 |
| Transcription Factor | NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 | CHEMBL3251 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0005488; binding | GO:0008270; zinc ion binding | 2.812E-11 | 3.602E-08 | AR, CA1, CA12, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9, ESRRA, MMP1, MMP2, MMP9, NR1H4, PTPN1, RORC, TP53 |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 7.906E-11 | 9.061E-08 | CYP1A1, CYP1A2, CYP1B1, CYP2A6, CYP2C19, CYP2C9 |
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 1.157E-10 | 1.200E-07 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9 |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 1.992E-10 | 1.885E-07 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, CYP3A4, NOX4 |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 2.205E-10 | 2.001E-07 | ALOX15, ALOX5, CYP1A1, CYP1A2, CYP1B1, CYP2A6, CYP2C19, CYP2C9, CYP3A4, XDH |
| BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 3.617E-10 | 3.029E-07 | CYP1A2, CYP2A6, CYP2C19, CYP2C9, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 2.096E-09 | 1.304E-06 | CYP1A2, CYP2C19, CYP2C9, CYP3A4 |
| MF | GO:0005488; binding | GO:0020037; heme binding | 1.580E-08 | 7.478E-06 | CYP1A1, CYP1A2, CYP1B1, CYP2A6, CYP2C19, CYP2C9, CYP3A4, NOX4 |
| BP | GO:0050896; response to stimulus | GO:0033993; response to lipid | 2.360E-08 | 1.049E-05 | ALPL, AR, BCHE, CA2, CA9, CYP1A1, CYP1A2, ESRRA, FLT3, HSD17B2, NFKB1, NR1H4, RORC, TP53, TYR |
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 1.665E-07 | 5.943E-05 | CYP1A2, CYP2C9, CYP3A4 |
| BP | GO:0009987; cellular process | GO:0071407; cellular response to organic cyclic compound | 3.941E-07 | 1.325E-04 | ALPL, APEX1, AR, CYP1A1, CYP1B1, FLT3, MAPK1, NFKB1, NOX4, RORC |
| BP | GO:0050896; response to stimulus | GO:0009725; response to hormone | 4.277E-07 | 1.411E-04 | ADRA2A, AKR1B1, ALPL, APEX1, AR, BCHE, CA2, CA9, CYP1A2, ESRRA, FLT3, NFKB1, TSHR |
| MF | GO:0005488; binding | GO:0005496; steroid binding | 5.727E-07 | 1.834E-04 | AR, CYP3A4, ESRRA, HSD17B1, NR1H4, RORC |
| MF | GO:0140110; transcription regulator activity | GO:0004879; nuclear receptor activity | 7.874E-07 | 2.381E-04 | AHR, AR, ESRRA, NR1H4, RORC |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 1.183E-06 | 3.388E-04 | CYP1A1, CYP1A2, CYP1B1, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0009820; alkaloid metabolic process | 1.446E-06 | 3.985E-04 | BCHE, CYP1A2, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:1901615; organic hydroxy compound metabolic process | 1.761E-06 | 4.733E-04 | AKR1B1, AKR1B10, ALDH1A1, ALOX15, CYP1A1, CYP1B1, CYP3A4, HIF1A, NR1H4, TYR |
| BP | GO:0050896; response to stimulus | GO:0034614; cellular response to reactive oxygen species | 2.194E-06 | 5.687E-04 | AKR1B1, APEX1, CYP1B1, MAPK1, MMP9, TP53 |
| MF | GO:0003824; catalytic activity | GO:0033764; steroid dehydrogenase activity, acting on the CH-OH group of donors, NAD or NADP as acceptor | 2.319E-06 | 5.941E-04 | HSD11B1, HSD17B1, HSD17B10, HSD17B2 |
| BP | GO:0008152; metabolic process | GO:0042446; hormone biosynthetic process | 2.378E-06 | 6.020E-04 | AKR1B1, CYP3A4, HSD11B1, HSD17B1, HSD17B2 |
| BP | GO:0009987; cellular process | GO:0097237; cellular response to toxic substance | 4.052E-06 | 9.387E-04 | AKR1B1, APEX1, CYP1B1, NFKB1, OPRD1, TP53 |
| BP | GO:0008152; metabolic process | GO:0070989; oxidative demethylation | 8.974E-06 | 1.879E-03 | CYP1A2, CYP2C9, CYP3A4 |
| BP | GO:0050896; response to stimulus | GO:0071417; cellular response to organonitrogen compound | 9.694E-06 | 1.988E-03 | AKR1B1, APEX1, MAPK1, MMP2, NFKB1, NOX4, NR1H4, TP53, TSHR |
| BP | GO:0008283; cell proliferation | GO:0042127; regulation of cell proliferation | 9.768E-06 | 1.988E-03 | ADRA2A, AHR, AKR1B1, AR, BCHE, CYP1B1, ESRRA, FLT3, HIF1A, LMNA, MAPK1, MMP2, MMP9, NOX4, PTPN2, TP53, TSHR, XDH |
| BP | GO:0050896; response to stimulus | GO:0033273; response to vitamin | 1.030E-05 | 2.077E-03 | ALPL, BCHE, CYP1A1, TP53, TYR |
| BP | GO:0009987; cellular process | GO:0006286; base-excision repair, base-free sugar-phosphate removal | 1.221E-05 | 2.417E-03 | APEX1, POLB |
| MF | GO:0003824; catalytic activity | GO:0003990; acetylcholinesterase activity | 1.221E-05 | 2.417E-03 | ACHE, BCHE |
| MF | GO:0003824; catalytic activity | GO:0016903; oxidoreductase activity, acting on the aldehyde or oxo group of donors | 1.715E-05 | 3.247E-03 | AKR1B1, AKR1B10, ALDH1A1, XDH |
| MF | GO:0003824; catalytic activity | GO:0008392; arachidonic acid epoxygenase activity | 2.739E-05 | 4.889E-03 | CYP2A6, CYP2C19, CYP2C9 |
| BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 3.655E-05 | 5.984E-03 | CA2, CA7 |
| BP | GO:0009987; cellular process | GO:0038183; bile acid signaling pathway | 3.655E-05 | 5.984E-03 | GPBAR1, NR1H4 |
| MF | GO:0003824; catalytic activity | GO:0070576; vitamin D 24-hydroxylase activity | 3.655E-05 | 5.984E-03 | CYP1A1, CYP3A4 |
| MF | GO:0060089; molecular transducer activity | GO:0004938; alpha2-adrenergic receptor activity | 3.655E-05 | 5.984E-03 | ADRA2A, ADRA2C |
| MF | GO:0060089; molecular transducer activity | GO:0038181; bile acid receptor activity | 3.655E-05 | 5.984E-03 | GPBAR1, NR1H4 |
| CC | GO:0016020; membrane | GO:0016323; basolateral plasma membrane | 4.905E-05 | 7.796E-03 | ABCC1, ADRA2A, CA2, CA4, CA9, TSHR |
| BP | GO:0050896; response to stimulus | GO:0055093; response to hyperoxia | 5.303E-05 | 8.308E-03 | CYP1A1, POLB, TP53 |
| MF | GO:0060089; molecular transducer activity | GO:0003707; steroid hormone receptor activity | 5.525E-05 | 8.594E-03 | AR, ESRRA, NR1H4, RORC |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 5.933E-25 | 1.292E-20 | CA1, CA12, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 3.081E-18 | 1.677E-14 | CA1, CA12, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 3.462E-17 | 1.508E-13 | CA1, CA12, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
| Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|
| hsa00910 | Nitrogen metabolism_Homo sapiens_hsa00910 | 3.650E-24 | 5.804E-22 | CA12; CA1; CA3; CA5B; CA2; CA5A; CA4; CA7; CA6; CA9; CA14 |
| hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 3.410E-10 | 2.711E-08 | HSD11B1; CYP2C9; CYP2A6; CYP1A2; CYP1A1; CYP1B1; CYP3A4; CYP2C19 |
| hsa00140 | Steroid hormone biosynthesis_Homo sapiens_hsa00140 | 1.002E-09 | 5.313E-08 | HSD11B1; HSD17B1; CYP1A2; HSD17B2; CYP1A1; CYP1B1; CYP3A4 |
| hsa05219 | Bladder cancer_Homo sapiens_hsa05219 | 5.048E-09 | 1.660E-07 | MMP1; DAPK1; MMP2; MAPK1; MMP9; TP53 |
| hsa01100 | Metabolic pathways_Homo sapiens_hsa01100 | 1.777E-08 | 4.709E-07 | GAA; ALOX15; AKR1B1; CYP2C19; CYP3A4; TYR; HSD17B10; HSD11B1; CYP2C9; CYP2A6; AKR1B10; HSD17B1; ALOX5; HSD17B2; CYP1A2; ALDH1A1; CYP1A1; ALPL; XDH |
| hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 5.219E-09 | 1.660E-07 | HSD11B1; CYP2C9; CYP2A6; CYP1A2; CYP1A1; CYP1B1; CYP3A4 |
| hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 8.700E-08 | 1.729E-06 | CYP2C9; CYP2A6; CYP1A2; ALDH1A1; CYP1A1; CYP3A4 |
| hsa05200 | Pathways in cancer_Homo sapiens_hsa05200 | 8.844E-07 | 1.278E-05 | AR; FLT3; MMP1; DAPK1; MMP2; MAPK1; HIF1A; TP53; MMP9; NFKB1 |
| hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 4.361E-08 | 9.905E-07 | CYP2C9; CYP1A2; ALOX15; CYP3A4; CYP2C19 |
| hsa04913 | Ovarian steroidogenesis_Homo sapiens_hsa04913 | 7.363E-07 | 1.171E-05 | HSD17B1; ALOX5; HSD17B2; CYP1A1; CYP1B1 |
| hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 3.715E-06 | 4.923E-05 | CYP2C9; CYP2A6; CYP1A2; CYP3A4; CYP2C19 |
| hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 3.962E-05 | 4.846E-04 | CYP2C9; ALOX5; ALOX15; MAPK1; CYP2C19 |
| hsa04071 | Sphingolipid signaling pathway_Homo sapiens_hsa04071 | 5.512E-05 | 6.229E-04 | OPRD1; ABCC1; MAPK1; TP53; NFKB1 |
| hsa00590 | Arachidonic acid metabolism_Homo sapiens_hsa00590 | 5.876E-05 | 6.229E-04 | CYP2C9; ALOX5; ALOX15; CYP2C19 |
| hsa05230 | Central carbon metabolism in cancer_Homo sapiens_hsa05230 | 7.972E-05 | 7.922E-04 | FLT3; MAPK1; TP53; HIF1A |
| hsa04520 | Adherens junction_Homo sapiens_hsa04520 | 1.176E-04 | 1.038E-03 | PTPN1; MAPK1; ACP1; PTPRF |
| hsa05215 | Prostate cancer_Homo sapiens_hsa05215 | 2.401E-04 | 1.909E-03 | AR; MAPK1; TP53; NFKB1 |
| hsa04976 | Bile secretion_Homo sapiens_hsa04976 | 1.000E-04 | 9.356E-04 | CA2; NR1H4; CYP3A4; ABCG2 |
| hsa05205 | Proteoglycans in cancer_Homo sapiens_hsa05205 | 6.364E-04 | 4.216E-03 | MMP2; MAPK1; TP53; HIF1A; MMP9 |
| hsa05206 | MicroRNAs in cancer_Homo sapiens_hsa05206 | 5.155E-04 | 3.564E-03 | ABCC1; CYP1B1; MAPK1; TP53; MMP9; NFKB1 |
| hsa04210 | Apoptosis_Homo sapiens_hsa04210 | 1.324E-03 | 8.096E-03 | LMNA; MAPK1; TP53; NFKB1 |
| hsa05161 | Hepatitis B_Homo sapiens_hsa05161 | 1.545E-03 | 8.773E-03 | MAPK1; TP53; MMP9; NFKB1 |
| hsa05221 | Acute myeloid leukemia_Homo sapiens_hsa05221 | 9.645E-04 | 6.135E-03 | FLT3; MAPK1; NFKB1 |
| hsa04080 | Neuroactive ligand-receptor interaction_Homo sapiens_hsa04080 | 2.516E-03 | 1.293E-02 | OPRD1; NMUR2; ADRA2C; ADRA2A; TSHR |
| hsa04022 | cGMP-PKG signaling pathway_Homo sapiens_hsa04022 | 2.521E-03 | 1.293E-02 | OPRD1; MAPK1; ADRA2C; ADRA2A |
| hsa05212 | Pancreatic cancer_Homo sapiens_hsa05212 | 1.476E-03 | 8.692E-03 | MAPK1; TP53; NFKB1 |
| hsa00380 | Tryptophan metabolism_Homo sapiens_hsa00380 | 3.394E-04 | 2.570E-03 | CYP1A2; CYP1A1; CYP1B1 |
| hsa05220 | Chronic myeloid leukemia_Homo sapiens_hsa05220 | 1.972E-03 | 1.081E-02 | MAPK1; TP53; NFKB1 |
| hsa00983 | Drug metabolism - other enzymes_Homo sapiens_hsa00983 | 5.139E-04 | 3.564E-03 | CYP2A6; CYP3A4; XDH |
| hsa05202 | Transcriptional misregulation in cancer_Homo sapiens_hsa05202 | 3.301E-03 | 1.590E-02 | FLT3; TP53; MMP9; NFKB1 |
| hsa04933 | AGE-RAGE signaling pathway in diabetic complications_Homo sapiens_hsa04933 | 4.939E-03 | 2.157E-02 | MMP2; MAPK1; NFKB1 |
| hsa05203 | Viral carcinogenesis_Homo sapiens_hsa05203 | 5.234E-03 | 2.157E-02 | POLB; MAPK1; TP53; NFKB1 |
| hsa00052 | Galactose metabolism_Homo sapiens_hsa00052 | 1.429E-04 | 1.196E-03 | AKR1B10; GAA; AKR1B1 |
| hsa04915 | Estrogen signaling pathway_Homo sapiens_hsa04915 | 4.671E-03 | 2.122E-02 | MMP2; MAPK1; MMP9 |
| hsa04066 | HIF-1 signaling pathway_Homo sapiens_hsa04066 | 5.216E-03 | 2.157E-02 | MAPK1; HIF1A; NFKB1 |
| hsa04668 | TNF signaling pathway_Homo sapiens_hsa04668 | 6.259E-03 | 2.370E-02 | MAPK1; MMP9; NFKB1 |
| hsa04931 | Insulin resistance_Homo sapiens_hsa04931 | 6.103E-03 | 2.367E-02 | PTPN1; NFKB1; PTPRF |
| hsa04919 | Thyroid hormone signaling pathway_Homo sapiens_hsa04919 | 7.594E-03 | 2.683E-02 | MAPK1; TP53; HIF1A |
| hsa05145 | Toxoplasmosis_Homo sapiens_hsa05145 | 7.594E-03 | 2.683E-02 | ALOX5; MAPK1; NFKB1 |
| hsa04722 | Neurotrophin signaling pathway_Homo sapiens_hsa04722 | 7.952E-03 | 2.748E-02 | MAPK1; TP53; NFKB1 |
| hsa05160 | Hepatitis C_Homo sapiens_hsa05160 | 1.052E-02 | 3.484E-02 | MAPK1; TP53; NFKB1 |
| hsa04910 | Insulin signaling pathway_Homo sapiens_hsa04910 | 1.185E-02 | 3.845E-02 | PTPN1; MAPK1; PTPRF |
| hsa05223 | Non-small cell lung cancer_Homo sapiens_hsa05223 | 1.559E-02 | 4.859E-02 | MAPK1; TP53 |
| hsa05213 | Endometrial cancer_Homo sapiens_hsa05213 | 1.354E-02 | 4.305E-02 | MAPK1; TP53 |
| hsa04621 | NOD-like receptor signaling pathway_Homo sapiens_hsa04621 | 1.612E-02 | 4.928E-02 | MAPK1; NFKB1 |
| hsa05216 | Thyroid cancer_Homo sapiens_hsa05216 | 4.358E-03 | 2.038E-02 | MAPK1; TP53 |
| hsa02010 | ABC transporters_Homo sapiens_hsa02010 | 9.828E-03 | 3.325E-02 | ABCC1; ABCG2 |
| hsa00051 | Fructose and mannose metabolism_Homo sapiens_hsa00051 | 5.290E-03 | 2.157E-02 | AKR1B10; AKR1B1 |
| hsa03410 | Base excision repair_Homo sapiens_hsa03410 | 5.619E-03 | 2.233E-02 | POLB; APEX1 |
| hsa00040 | Pentose and glucuronate interconversions_Homo sapiens_hsa00040 | 6.660E-03 | 2.463E-02 | AKR1B10; AKR1B1 |
| hsa04964 | Proximal tubule bicarbonate reclamation_Homo sapiens_hsa04964 | 2.752E-03 | 1.367E-02 | CA2; CA4 |
| hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 3.741E-07 | 6.609E-06 | CYP2A6; CYP1A2; XDH |
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| C00-D49: Neoplasms | Pancreatic cancer | C25 | FLT3; MMP2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Premature ejaculation | F52.4 | OPRD1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Pompe's disease | E74.02 | GAA |
| G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE |
| L00-L99: Diseases of the skin and subcutaneous tissue | Erythema | L51-L54 | ADRA2C |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic complication | E08-E13 | AKR1B1 |
| I00-I99: Diseases of the circulatory system | Hypertension | I10-I16 | ADRA2C |
| NA: NA | Acute nonspecific diarrhea | NA | OPRD1 |
| G00-G99: Diseases of the nervous system G00-G99 | Acute migraine | G43 | OPRD1 |
| C00-D49: Neoplasms | Acute lymphoblastic leukemia | C91.0 | FLT3 |
| C00-D49: Neoplasms | Myelofibrosis | C94.4, D47.4 | FLT3 |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE |
| A00-B99: Certain infectious and parasitic diseases | Fungal infections | B35-B49 | ALOX5 |
| C00-D49: Neoplasms | Colon cancer | C50 | FLT3; ALPL |
| I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | AR |
| NA: NA | Hematopoietic stem cell transplantation | NA | FLT3 |
| A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE |
| C00-D49: Neoplasms | Hematological malignancies | C81-C86 | TP53 |
| C00-D49: Neoplasms | Female androgenresponsive recurrent mammary cancer | C50 | AR |
| J00-J99: Diseases of the respiratory system | Airway inflammation | J00-J99 | FLT3 |
| C00-D49: Neoplasms | Hormone refractory prostate cancer | C61 | AR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | AR |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Schizophrenia | F20 | ESRRA |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Sexual dysfunction | F52 | ADRA2A |
| A00-B99: Certain infectious and parasitic diseases | Lymphatic filariasis | B74 | ALOX5 |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | HIF1A; CA9 |
| Z00-Z99: Factors influencing health status and contact with health services | Contraception | Z30 | AR |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | HSD11B1; ADRA2C; CA4; CA4 |
| J00-J99: Diseases of the respiratory system | Rhinitis | J00, J30, J31.0 | ALOX5 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | ALOX5; TYR; OPRD1; MMP1; AKR1B1; ESRRA |
| C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | TP53 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Lipid metabolism disorder | E75-E78 | HSD11B1 |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | ADRA2C; ACHE; ACHE; ACHE |
| I00-I99: Diseases of the circulatory system | Heart failure | I50 | AR; XDH; ADRA2C |
| G00-G99: Diseases of the nervous system G00-G99 | Spinal muscular atrophy | G00-G99 | SMN1;SMN2 |
| C00-D49: Neoplasms | Bladder cancer | C67 | AR |
| I00-I99: Diseases of the circulatory system | Ischemic heart diseases | I20-I25 | OPRD1 |
| K00-K95: Diseases of the digestive system | Gastrointestinal disease | K00-K93 | ESRRA |
| Q00-Q99: Congenital malformations, deformations and chromosomal abnormalities | Genetic disease | Q00-Q99 | ALPL |
| L00-L99: Diseases of the skin and subcutaneous tissue | Pruritus | L29 | ALOX5 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2 |
| J00-J99: Diseases of the respiratory system | Influenza virus | J11.1 | HSD11B1 |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | ALOX5 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | ALOX5 |
| G00-G99: Diseases of the nervous system G00-G99 | Encephalopathy | G93.4 | XDH |
| E00-E89: Endocrine, nutritional and metabolic diseases | Endocrine disease | E00-E35 | AR |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | CA1; CA1; AKR1B1; ADRA2C; ACHE |
| C00-D49: Neoplasms | Gliosarcoma | NA | FLT3 |
| C00-D49: Neoplasms | Glioblastoma | NA | FLT3 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | XDH; AKR1B1; ABCC1; ABCC1 |
| H60-H95: Diseases of the ear and mastoid process | Hearing disorder | H90.5 | TP53 |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | TP53; AKR1B1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Muscle atrophy | M62.5 | AR |
| C00-D49: Neoplasms | Multiple myeloma | C90 | AHR |
| I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A |
| C00-D49: Neoplasms | Myeloid leukemia | C92 | FLT3 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE |
| L00-L99: Diseases of the skin and subcutaneous tissue | Vitiligo | L80 | TYR |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | ALOX5; FLT3 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic syndrome x | E88.81 | HSD11B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic disorders | E70-E89 | GPBAR1; HSD11B1 |
| C00-D49: Neoplasms | Metastatic castration-resistant prostate cancer | C61 | AR |
| NA: NA | Anaplastic mixed oligoastrocytoma | NA | FLT3 |
| H00-H59: Diseases of the eye and adnexa | Choroidal neovascularisation | H35 | ESRRA |
| C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Toxicity | T36-T50, T51-T65 | TP53 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | PTPN1; PTPN1; GPBAR1; HSD11B1; NFKB1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Atopic dermatitis | L00-L99 | ALOX5 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Attention deficit hyperactivity disorder | F90 | ADRA2A |
| A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | CYP2C9 |
| J00-J99: Diseases of the respiratory system | Respiratory disease | J00-J99 | ALOX5 |
| I00-I99: Diseases of the circulatory system | Restenosis | I51.89 | MAPK1 |
| C00-D49: Neoplasms | Renal cancer | C64 | CA9 |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | ADRA2C |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | ACHE |
| C00-D49: Neoplasms | Melanoma | C43 | TYR |
| L00-L99: Diseases of the skin and subcutaneous tissue | Melasma | L81.1 | TYR |
| C00-D49: Neoplasms | Oral cavity cancer | C00-C08 | TP53 |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | HIF1A; TP53; FLT3; CA9; MAPK1; MMP2; MMP9 |
| K00-K95: Diseases of the digestive system | Ulcerative colitis | K51 | MMP9 |
| NA: NA | Colour dead tissues | NA | PTPN1 |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | ALOX5; ALOX5; ADRA2C; ESRRA |
| I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | ALOX5; HSD11B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Cystic fibrosis | E84 | AR |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Cough | R05 | OPRD1 |
| C00-D49: Neoplasms | Non-small-cell lung cancer | NA | MMP2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | HSD11B1; ESRRA |
| NA: NA | Male hypogonadism | NA | AR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Male hormonal deficiencies | E20-E35 | AR |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Male sexual disorders | F52 | ADRA2C |
| C00-D49: Neoplasms | Lung cancer | C33-C34 | MMP2 |
| I00-I99: Diseases of the circulatory system | Stroke | I61-I63, I80-I82 | MMP9 |
| C00-D49: Neoplasms | Ocular cancer | C69 | APEX1 |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA2; ACHE; CA4 |
| C00-D49: Neoplasms | Leukemia | C90-C95 | FLT3 |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | CA1; ACHE |
| NA: NA | Chronic diarrhea associated with inflammatory bowel disease | NA | OPRD1 |
| A00-B99: Certain infectious and parasitic diseases | Human immunodeficiency virus infection | B20-B26 | FLT3 |
| I00-I99: Diseases of the circulatory system | Renal artery disease | I70.1 | TP53 |
| C00-D49: Neoplasms | Renal cell carcinoma | NA | MMP2 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | ALOX5; MMP2 |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; CA1 |
| K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE |
| H00-H59: Diseases of the eye and adnexa | Ocular disease | H00-H59 | ADRA2C |
| J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | ALOX5 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | AR |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis in post-menopausal women | M80-M81 | AR |
| C00-D49: Neoplasms | Ovarian cancer | C56 | MMP2 |
| C00-D49: Neoplasms | Overactive bladder disorder | C67, N32.81 | OPRD1 |
| NA: NA | GIST | NA | FLT3 |
| A00-B99: Certain infectious and parasitic diseases | Anthelmintic | B89 | ALPL |
| C00-D49: Neoplasms | CLL | NA | FLT3 |
| C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | ACHE |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | ACHE |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | AR; OPRD1; ADRA2C; ADRA2A; ACHE |
| K00-K95: Diseases of the digestive system | Peptic ulcer | K25-K27 | ADRA2C |
| A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatological disease | L00-L99 | AR; ESRRA |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | PTPN1; HSD11B1; HSD11B1; AKR1B1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatitis | L20-L30 | ALOX5; ESRRA |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Depression | F30-F39 | ADRA2C |
| C00-D49: Neoplasms | Thyroid cancer | C73 | TSHR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Testosterone deficiency | E29.1 | AR |
| I00-I99: Diseases of the circulatory system | Thrombosis | I80-I82 | ALOX5 |
| N00-N99: Diseases of the genitourinary system | Bladder disease | N30-N32 | OPRD1 |
| C00-D49: Neoplasms | Metastatic prostate cancer | C61 | AR |
| C00-D49: Neoplasms | Breast cancer | C50 | AR; FLT3; FLT3; CA9 |
| K00-K95: Diseases of the digestive system | Diarrhea-predominant IBS | K58.0 | OPRD1 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Contusion | S36.220S | ADRA2C |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Fibromyalgia | M79.7 | ADRA2C |
| NA: NA | HIV infections | NA | AHR |
| C00-D49: Neoplasms | AML | NA | FLT3 |
| C00-D49: Neoplasms | Advanced prostate cancer | C61 | AR |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | OPRD1; CYP3A4; ACHE |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Cachexia | R64 | AR; ESRRA |
| C00-D49: Neoplasms | Cancer | C00-C96 | AR; HIF1A; TP53; CA1; FLT3; FLT3; CA9; MAPK1; NFKB1; MMP2; ACHE; MMP9 |
| N00-N99: Diseases of the genitourinary system | Urinary incontinence | N39.3, N39.4, R32 | OPRD1 |
| N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | ALOX5; MMP1; ABCC1; ESRRA |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | AKR1B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic nephropathy | E11.21 | MMP1; ADRA2C |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic cataract | E10.36, E11.36 | AKR1B1 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ADRA2C; ACHE |
| C00-D49: Neoplasms | Castration-resistant prostate cancer | C61 | AR |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Allergy | T78.4 | ALOX5 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Alopecia | L65.9 | AR |
| J00-J99: Diseases of the respiratory system | Allergic rhinitis | J00, J30, J31.0, T78.4 | ADRA2C; ESRRA |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | TP53; TP53; FLT3; FLT3 |
| C00-D49: Neoplasms | Prostate cancer | C61 | AR; AR; FLT3 |
| N00-N99: Diseases of the genitourinary system | Prostate hyperplasia | N40 | AR |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2 |
| NA: NA | Edema | NA | CA2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | PTPN1; HSD11B1; ADRA2C |
| I00-I99: Diseases of the circulatory system | Hypotension | I95 | ADRA2C |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricaemia in gout | E79.0, M10 | XDH |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricemia | E79.0 | XDH |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypogonadism | E23.0, E28.3, E29.1 | AR |
| NA: NA | Upper abdominal bloating | NA | ACHE |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | OPRD1; ADRA2C |
| K00-K95: Diseases of the digestive system | Alcoholic hepatitis | K70.1 | AR |
| NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Moderate-to-severe pain | R52, G89 | OPRD1 |
| A00-B99: Certain infectious and parasitic diseases | Infections | A00-B99 | PTPN1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | OPRD1 |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | TP53; FLT3; MMP9 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | AR; AR; MMP2; ESRRA |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypercholesterolemia | E78 | HSD11B1 |